<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03460509</url>
  </required_header>
  <id_info>
    <org_study_id>SIVAA01</org_study_id>
    <nct_id>NCT03460509</nct_id>
  </id_info>
  <brief_title>Reversal With Low Doses of Sugammadex in Patients Undergoing Non-cardiac Surgery</brief_title>
  <official_title>A Randomized Double Blind Trial Comparing Reversal With Low Doses Of Sugammadex aFter Rocuronium-induced Neuromuscular Block Under General Anesthesia in Patients Undergoing Non-cardiac Surgery(TOF TRIAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital of Vestfold</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital of Vestfold</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuromuscular blocking agents (NMBA) are among the most commonly used drugs during general&#xD;
      anesthesia and may induce complete muscle paralysis.They are used clinically to facilitate&#xD;
      endotracheal intubation and to optimize surgical working conditions. Incomplete recovery from&#xD;
      non-depolarising NMBAs continues to be a common problem in modern postoperative care unit and&#xD;
      is associated with significant risk of microaspiration and hypoventilation which leads to&#xD;
      pulmonary complications.Recently effective reversal of neuromuscular blockade has been&#xD;
      described by use of lower dose of sugammadex the recommended without providing adequate&#xD;
      answer to whether the lower dose is safe enough to avoid recurrent block.&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
        1. Administration of sugammadex 0.25 mg/kg at TOF ratio 0.3 will successfully reverse&#xD;
           (TOF=0.9) rocuronium induced neuromuscular block within 10 min.&#xD;
&#xD;
        2. Recurrent block (TOF ratio &lt; 0.9) does not occur after reversal with low dose sugammadex&#xD;
           0.25 mg/kg.&#xD;
&#xD;
      The primary objective of this trial is to assess the dose-response characteristics of&#xD;
      sugammadex in reversing rocuronium induced neuromuscular block and to identify the minimal&#xD;
      effective dose&#xD;
&#xD;
      Secondary objective is to assess the safety of different doses of sugammadex (recurrent block&#xD;
      (TOF ratio &lt; 0.9) after reversal and the occurrence of adverse reactions)&#xD;
&#xD;
      Sugammadex is a very expensive drug which limits its use i anaesthesia department. By&#xD;
      optimising drug dosage it may have economic impact and contribute to a wider use of&#xD;
      sugammadex to reverse neuromuscular block before extubation and thus avoid incomplete&#xD;
      recovery. This may lead to less risk for postoperative pulmonary complications and thereby&#xD;
      reduce morbidity and mortality after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Doses of study drug will be 0 mg/kg Ideal Body Weight (IBW), 0.25 mg/kg IBW, 0.50 mg/kg IBW,&#xD;
      1.0 mg/kg IBW and 2.0 mg/kg IBW. TOF will be measured every 10th second until full reversal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">August 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time from study drug administration to reaching a TOF ratio of 0.9.</measure>
    <time_frame>10 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patient with reoccurrence of neuromuscular block after initial reversal to TOF ratio 0.9.</measure>
    <time_frame>20 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse reactions in each group</measure>
    <time_frame>until discharge - 3 days</time_frame>
    <description>Adverse reactions (anaphylactic reaction, flushing, urticaria, erythematous rash, (severe) hypotension (BPsyst&gt; 75 mmHg), tachycardia (heart rate&gt; 120 beats/min), bradycardia (heart rate &lt;40 beats/min), swelling of tongue, swelling of pharynx, bronchospasm)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Postoperative Residual Curarization</condition>
  <condition>Neuromuscular Block</condition>
  <arm_group>
    <arm_group_label>Sugammadex 0 mg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo NaCl 0,9%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 0,25 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sugammadex 0.25 mg/kg IBW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 0,5 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sugammadex 0.50 mg/kg IBW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 1mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sugammadex 1.0 mg/kg IBW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 2mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sugammadex 2 mg/kg IBW</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Dose-response</description>
    <arm_group_label>Sugammadex 0 mg/kg</arm_group_label>
    <arm_group_label>Sugammadex 0,25 mg/kg</arm_group_label>
    <arm_group_label>Sugammadex 0,5 mg/kg</arm_group_label>
    <arm_group_label>Sugammadex 1mg/kg</arm_group_label>
    <arm_group_label>Sugammadex 2mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient, both genders, undergoing any elective in-hospital surgical procedure under&#xD;
             general anesthesia requiring rocuronium neuromuscular block.&#xD;
&#xD;
          -  ASA I-IV&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient less than 18 years of age&#xD;
&#xD;
          -  Patient participating in another clinical study which could interfere with TOF trial.&#xD;
&#xD;
          -  Patient with neuromuscular disease&#xD;
&#xD;
          -  Patient from ICU&#xD;
&#xD;
          -  BMI &gt; 30.0 kg/m2&#xD;
&#xD;
          -  Patient scheduled for local or regional anesthesia only&#xD;
&#xD;
          -  Patient undergoing general anesthesia without rocuronium&#xD;
&#xD;
          -  Patient with hypersensitivity to NMBAs or sugammadex. Also hypersensitivity to any&#xD;
             active substance or to any of the following excipient: Hydrochloric acid 3.7% (to&#xD;
             adjust pH) and/or sodium hydroxide (to adjust pH) Water for injections .&#xD;
&#xD;
          -  Renal dysfunction (GFR&lt;30 mL/min/1,73m2)&#xD;
&#xD;
          -  Hepatic dysfunction&#xD;
&#xD;
          -  Patient who have received sugammadex in the last 24 h.&#xD;
&#xD;
          -  Pregnant or breastfeeding woman. Women in childbearing age must have a negative&#xD;
             pregnant test before inclusion.&#xD;
&#xD;
          -  Bradycardia (puls &lt;40)&#xD;
&#xD;
          -  Hypotension (Systolic BP &lt;90 mmHg)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tayyba Aslam, MD</last_name>
    <phone>004798097489</phone>
    <email>tayybaaslam@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Espen Lindholm, MD, PHD</last_name>
    <phone>004792213346</phone>
    <email>espen.lindholm@siv.no</email>
  </overall_contact_backup>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>March 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <last_update_submitted>May 27, 2018</last_update_submitted>
  <last_update_submitted_qc>May 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital of Vestfold</investigator_affiliation>
    <investigator_full_name>Tayyba Aslam</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delayed Emergence from Anesthesia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

